What is atezolizumab studying for peritoneal mesothelioma?

Atezolizumab is being studied to see if adding it to standard chemotherapy and bevacizumab improves treatment response in patients with peritoneal mesothelioma. Researchers want to find out if this combination helps control the cancer better and affects survival. The National Cancer Institute sponsors this research to explore new treatment options.

Who may be eligible for this peritoneal mesothelioma clinical trial?

Adults aged 18 or older with confirmed malignant peritoneal mesothelioma who have not had prior treatment may be eligible. Both men and women can join if they meet health criteria like good blood counts and no active infections. People with certain medical conditions or autoimmune diseases might not qualify. Please review eligibility criteria for more details.

Is there any cost to participate in this peritoneal mesothelioma clinical trial?

Study-related care, including the study drugs and all trial visits, is provided at no cost. However, personal travel and related expenses may vary and are not guaranteed to be covered. Participants should plan for any costs related to getting to and from study visits.

Actively Recruiting

Phase 2

Age: 18Years +

All Genders

ID05001880

Phase 2 Study Comparing Chemotherapy With or Without Immunotherapy for Treating Peritoneal Mesothelioma

Led by National Cancer Institute (NCI) · Updated on 2026-07-31

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

This trial studies adults with malignant peritoneal mesothelioma, comparing standard treatment alone to standard treatment combined with immunotherapy using atezolizumab. It aims to determine if adding atezolizumab to chemotherapy and bevacizumab improves response rates and survival. The study also explores safety, metabolic responses, surgical outcomes, and blood-based biomarkers related to treatment effects. Participants are randomly assigned to one of two groups. One group receives a combination of atezolizumab, bevacizumab, carboplatin, and pemetrexed intravenously every 21 days for up to four cycles, followed by cytoreductive surgery and HIPEC within 4 to 8 weeks. Those not eligible for surgery continue maintenance treatment with atezolizumab and bevacizumab. The other group receives bevacizumab, carboplatin, and pemetrexed on the same schedule, followed by surgery and HIPEC or maintenance bevacizumab with or without atezolizumab. Throughout the study, participants undergo CT and PET scans and provide blood and tissue samples for analysis. After completing treatment, patients are followed every six months for up to three years to assess outcomes including response rates, survival, safety, and pathological effects. The study measures these outcomes using imaging criteria and clinical evaluations to understand treatment benefits and risks.

CONDITIONS

Brief Title

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Adults aged 18 years or older
Histologically or cytologically confirmed malignant peritoneal mesothelioma with no prior treatment
Measurable disease per RECIST v1.1
ECOG performance status 0-1
Leukocytes ≥ 2,500/mm³
Absolute neutrophil count ≥ 1,500/mm³
Platelet count ≥ 100,000/mm³
Creatinine clearance ≥ 45 mL/min/1.73 m² if creatinine elevated
Total bilirubin ≤ 1.5 times upper limit of normal
AST/ALT ≤ 3.0 times upper limit of normal
Urine protein/creatinine ratio < 1 or urine protein ≤ 1+
Not pregnant or nursing with negative pregnancy test within 28 days for women of childbearing potential
Willingness to use effective birth control if of reproductive potential
No prior systemic therapy for peritoneal mesothelioma
No active second malignancy except certain skin cancers or cervical carcinoma in situ
Controlled autoimmune-related hypothyroidism or type 1 diabetes on stable treatment
Patients with HIV, HBV, or HCV under specified treatment and viral control conditions eligible

You will not qualify if you...

Psychiatric illness preventing informed consent
Uncontrolled infection, diabetes, or cardiac disease considered hazardous
Active second malignancy other than excluded conditions
Active or history of autoimmune disease or immune deficiency except specified exceptions
Eczema, psoriasis, or similar dermatologic conditions exceeding 10% body surface area or requiring high-potency treatments
History of lung diseases like idiopathic pulmonary fibrosis or pneumonitis
Prior allogeneic stem cell or solid organ transplant
Untreated or unstable CNS metastases
Recent live attenuated vaccine within 30 days prior to treatment
Uncontrolled hypertension or serious cardiovascular or vascular disease
History of severe venous thromboembolism
Significant bleeding disorders or recent bleeding episodes
Major surgery or trauma within 28 days before treatment
Core biopsy or minor surgery within 7 days before treatment
Active infection requiring IV antibiotics at treatment start
Recent abdominal fistula, GI perforation, abscess, or bleeding
Serious non-healing wounds or untreated fractures
Other malignancies within 5 years except localized in situ cancers
Use of immunosuppressive medications within 2 weeks before treatment except allowed exceptions
Use of NSAIDs around pemetrexed administration for certain creatinine clearance levels

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Phase 2 Study Comparing Chemotherapy With or Without Immunotherapy for Treating Peritoneal Mesothelioma

On this page

AI-Summary

What this Trial Is About

Brief Title

Who Can Participate

Eligibility Criteria

Not the Right Trial for You?

On this page

Who Can Participate

Eligibility Criteria